Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.

Abstract

In this platinum-pretreated population of advanced UC, the addition of vandetanib to docetaxel did not result in a significant improvement in PFS, ORR, or OS. The toxicity of vandetanib plus docetaxel was greater than that for vendetanib plus placebo. Single-agent vandetanib activity was minimal.

Full Text

• DOI - Journal of clinical oncology : official journal of the American Society of Clinical Oncology (DOI)
• HighWire Press - full-text online
• EBSCO - full-text online

Subjects

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols
• Carcinoma
• Disease Progression
• Disease-Free Survival
• Double-Blind Method
• Female
• Humans
• Kaplan-Meier Estimate
• Male
• Middle Aged
• Multivariate Analysis
• Piperidines
• Platinum Compounds
• Prognosis
• Proportional Hazards Models
• Protein Kinase Inhibitors
• Protein-Tyrosine Kinases
• Quinazolines
• Risk Factors
• Taxoids
• Treatment Failure
• Urologic Neoplasms
• Urothelium

Similar articles

• Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. (2007-09-19)
• Vandetanib Plus Chemotherapy for Induction Followed by Vandetanib or Placebo As Maintenance for Patients with Advanced Non-Small-Cell Lung Cancer: A Randomized Phase 2 PrECOG Study (PrE0501). (2013-05-17)
• Phase II Study of Cetuximab in Combination with Docetaxel in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck after Platinum-Containing Therapy: A Multicenter Study of the Arbeitsgemeinschaft Internistische Onkologie. (2013-02-26)
• Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial. (2012-09-10)
• Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. (2008-11-25)
• [Docetaxel (TXT) and irinotecan (CPT-11) as a second-line chemotherapy for platinum-pretreated squamous cell carcinoma of the head and neck] (2008-08-14)
• Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer. (2007-08-02)
• Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. (2010-07-09)
• Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. (2010-02-16)

Authors

• Toni K Choueiri
• Robert W Ross
• Susanna Jacobus
• Ulka Vaishampayan
• Evan Y Yu
• David I Quinn
• Noah M Hahn
• Thomas E Hutson
• Guru Sonpavde
• Stephanie C Morrissey
• Geoffrey C Buckle
• William Y Kim
• Daniel P Petrylak
• Christopher W Ryan
• Mario A Eisenberger
• Amir Mortazavi

Publication date

2012-02-13

Journal

Journal topics

• Medical Oncology

Language

Eng.

Copyright

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Dana-Farber Cancer Institute, Boston, MA 02215, USA. Toni_Choueiri [at] dfci.harvard.edu

Release reference

J Clin Oncol. 2012 Feb;30(5):507-12

Related books

• Books of Antineoplastic Combined Chemotherapy Protocols
• Books of Carcinoma
• Books of Disease Progression
• Books of Disease-Free Survival
• Books of Double-Blind Method
• Books of Kaplan-Meier Estimate
• Books of Medical Oncology
• Books of Multivariate Analysis
• Books of Piperidines
• Books of Platinum Compounds
• Books of Prognosis
• Books of Proportional Hazards Models
• Books of Protein Kinase Inhibitors
• Books of Protein-Tyrosine Kinases
• Books of Quinazolines
• Books of Risk Factors
• Books of Taxoids
• Books of Treatment Failure
• Books of Urologic Neoplasms
• Books of Urothelium